These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 23240787)

  • 41. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.
    Roujeau JC; Kelly JP; Naldi L; Rzany B; Stern RS; Anderson T; Auquier A; Bastuji-Garin S; Correia O; Locati F
    N Engl J Med; 1995 Dec; 333(24):1600-7. PubMed ID: 7477195
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The use of dabigatran immediately after atrial fibrillation ablation.
    Winkle RA; Mead RH; Engel G; Kong MH; Patrawala RA
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):264-8. PubMed ID: 21955008
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ciprofloxacin-induced toxic epidermal necrolysis.
    Moshfeghi M; Mandler HD
    Ann Pharmacother; 1993 Dec; 27(12):1467-9. PubMed ID: 8305780
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Toxic epidermal necrolysis after cranial radiotherapy and phenytoin treatment.
    Oner Dincbas F; Yörük S; Demirkesen C; Uzel O; Koca S
    Onkologie; 2004 Aug; 27(4):389-92. PubMed ID: 15347896
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
    Pisters R; Nieuwlaat R; Lane DA; Crijns HJ; Lip GY
    Thromb Haemost; 2013 Feb; 109(2):328-36. PubMed ID: 23179181
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
    Hohnloser SH; Oldgren J; Yang S; Wallentin L; Ezekowitz M; Reilly P; Eikelboom J; Brueckmann M; Yusuf S; Connolly SJ
    Circulation; 2012 Feb; 125(5):669-76. PubMed ID: 22215856
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of the experience with paediatric patients in a university hospital.
    Ferrándiz-Pulido C; García-Fernández D; Domínguez-Sampedro P; García-Patos V
    J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1153-9. PubMed ID: 21198948
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial.
    Bytzer P; Connolly SJ; Yang S; Ezekowitz M; Formella S; Reilly PA; Aisenberg J
    Clin Gastroenterol Hepatol; 2013 Mar; 11(3):246-52.e1-5. PubMed ID: 23103906
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Bullous drug eruption with Nigella sativa oil].
    Gelot P; Bara-Passot C; Gimenez-Arnau E; Beneton N; Maillard H; Celerier P
    Ann Dermatol Venereol; 2012 Apr; 139(4):287-91. PubMed ID: 22482483
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
    Prescrire Int; 2012 Feb; 21(124):33-6. PubMed ID: 22413715
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dabigatran for stroke prevention in all patients with atrial fibrillation?
    Hunchuck JE; Lake JD
    Pharmacotherapy; 2011 Aug; 31(8):725-8. PubMed ID: 21923597
    [No Abstract]   [Full Text] [Related]  

  • 52. [Stevens-Johnson syndrome and toxic epidermal necrolysis in children].
    Sotelo-Cruz N
    Gac Med Mex; 2012; 148(3):265-75. PubMed ID: 22820360
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective.
    Mockenhaupt M; Kelly JP; Kaufman D; Stern RS;
    J Rheumatol; 2003 Oct; 30(10):2234-40. PubMed ID: 14528522
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hemorrhagic complications associated with dabigatran use.
    Chen BC; Viny AD; Garlich FM; Basciano P; Howland MA; Smith SW; Hoffman RS; Nelson LS
    Clin Toxicol (Phila); 2012 Nov; 50(9):854-7. PubMed ID: 22970730
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Toxic epidermal necrolysis/Stevens-Johnson syndrome: current trends in management.
    Dalli RL; Kumar R; Kennedy P; Maitz P; Lee S; Johnson R
    ANZ J Surg; 2007 Aug; 77(8):671-6. PubMed ID: 17635282
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Toxic epidermal necrolysis (syndrome Lyell) versus Stevens-Johnson syndrome].
    Jezierska-Krupa B; Hyla-Klekot L
    Pediatr Pol; 1996 Jul; 71(7):615-20. PubMed ID: 8803466
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A review of causes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children.
    Ferrandiz-Pulido C; Garcia-Patos V
    Arch Dis Child; 2013 Dec; 98(12):998-1003. PubMed ID: 23873883
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiretroviral-induced toxic epidermal necrolysis in a patient positive for human immunodeficiency virus.
    Pahk R; Azu MC; Taira BR; Sandoval S
    Clin Exp Dermatol; 2009 Dec; 34(8):e775-7. PubMed ID: 19778313
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ethambutol-induced toxic epidermal necrolysis.
    Pegram PS; Mountz JD; O'Bar PR
    Arch Intern Med; 1981 Nov; 141(12):1677-8. PubMed ID: 7305578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.